|Articles|July 15, 2008
Akorn ophthalmic gel given approvable letter
Akorn Inc. has received an FDA approvable letter for an ocular topical anesthetic 3.5% (Akten Ophthalmic Gel).
Advertisement
Buffalo Grove, IL-Akorn Inc. has received an FDA approvable letter for an ocular topical anesthetic 3.5% (Akten Ophthalmic Gel).
The letter identified several minor deficiencies that have been addressed in previous submissions, according to the company, and the deficiencies need to be rectified before final approval is granted.
No additional clinical data were required for the remaining response submitted to the FDA.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Metformin use associated with reduced incidence of intermediate AMD
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5
























